摘要
目的:探讨西妥昔单抗联合FP(5-氟尿嘧啶+顺铂)方案治疗中晚期食管癌的疗效及对血清鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)水平和生存质量的影响。方法:选取我院2013年11月至2016年1月中晚期食管癌患者86例,采用随机数字表法分为对照组(n=43)与研究组(n=43)。对照组采取FP化疗方案,研究组于对照组基础上加用西妥昔单抗,3周为1个周期,持续治疗4个周期。统计两组临床疗效、治疗前及疗程结束后血清SCC及CEA水平、生存质量(EORTC QLQ-C30)分值、毒副反应发生率,随访12～24个月,统计两组生存率。结果:临床疗效:研究组总有效率(72. 09%)高于对照组(60. 47%),有进一步获益可能,但差异不显著(P> 0. 05)。肿瘤标志物:治疗前两组血清SCC及CEA水平间无显著差异(P> 0. 05),疗程结束后两组血清SCC及CEA水平较治疗前降低,且研究组低于对照组(P <0. 05)。生存质量:治疗前两组EORTC QLQ-C30分值间无显著差异(P> 0. 05),疗程结束后两组EORTC QLQ-C30分值较治疗前增高,且研究组高于对照组(P <0. 05)。毒副反应:两组均未发生Ⅳ度毒副反应,且研究组肝肾功能异常、呕吐恶心、血红蛋白减少、白细胞减少发生率与对照组相比无明显差异(P> 0. 05)。生存率:研究组治疗后12个月、18个月、24个月生存率(86. 05%、74. 42%、55. 81%)高于对照组(79. 07%、62. 79%、44. 19%),但无显著差异(P> 0. 05)。结论:采取FP方案联合西妥昔单抗治疗中晚期食管癌,可降低血清SCC、CEA水平,改善疾病治疗效果,利于提高患者生存质量,且毒副反应发生率较低,均可耐受,还可降低病死率,延长患者生存期。
Objective:To explore the efficacy of cetuximab combined with FP chemotherapy in the treatment of advanced esophageal cancer and its effect on serum carcinoembryonic antigen(CEA) and squamous cell carcinoma antigen(SCC) levels and quality of life.Methods:86 patients with advanced esophageal cancer from November 2013 to January 2016 in our hospital were randomly divided into control group(n=43) and study group(n=43).The control group received FP chemotherapy,while the study group received cetuximab on the basis of the control group.The 3 weeks was 1 cycle,and the treatment lasted 4 cycles.The clinical efficacy,serum levels of SCC and CEA before and after treatment,quality of life(EORTC QLQ-C30) score and incidence of side effects were compared between the two groups.The two groups were followed up for 12~24 months,and the two groups of survival rates were counted.Results: The total effective rate of the study group(72.09%) was higher than that of the control group(60.47%),and further benefit was possible,but the difference was not significant(P>0.05).There was insignificant difference in serum levels of SCC and CEA between the two groups before treatment(P>0.05).After treatment,the serum levels of SCC and CEA of the two groups were lower than those before treatment,and the study group was lower than the control group(P<0.05).There was insignificant difference in the EORTC QLQ-C30 scores between the two groups before treatment(P>0.05).After treatment,the EORTC QLQ-C30 scores of the two groups were higher than those before treatment,and the study group was higher than that of the control group(P<0.05).None of the two groups had IV degree of toxic and side effects,and there was insignificant difference in the incidence of liver and kidney function,vomiting and nausea,hemoglobin reduction and leukocyte reduction in the study group compared with the control group(P>0.05).The 12-month,18-month,and 24-month survival rates of the study group(86.05%,74.42%,55.81%) were higher than those of the control group(79.07%,62.79%,44.19%),but there was insignificant difference(P>0.05).Conclusion:FP regimen combined with cetuximab can reduce the level of serum SCC and CEA,improve the effect of disease treatment,improve the quality of life of the patients,and have a low incidence of side effects and it can be tolerated.It can also reduce the mortality of the disease and prolong the life period of the patients.
作者
韩玉秋
郑德文
杜振元
Han Yuqiu;Zheng Dewen;Du Zhenyuan(Pharmaceutical Preparation Section,Chaoyang No.2 Hospital,Liaoning Chaoyang 122000,China;Internal Medicine-Oncology,Chaoyang No.2 Hospital,Liaoning Chaoyang 122000,China;Clinical Laboratory,Chaoyang No.2 Hospital,Liaoning Chaoyang 122000,China)
出处
《现代肿瘤医学》
CAS
2019年第8期1339-1344,共6页
Journal of Modern Oncology
